3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
45
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Recurrence
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Inflammatory Breast Neoplasms
1
HER2 Positive Breast Cancer
1
Genomic Instability
1
Cholangiocarcinoma
1
Breast Cancer Metastatic
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Cyclophosphamide
20
Trastuzumab
12
Epirubicin
12
Doxorubicin
12
Docetaxel
11
Paclitaxel
10
Filgrastim
8
Carboplatin
7
Radiotherapy
6
Bevacizumab
5
Neoadjuvant Therapy
4
Lapatinib
4
Granulocyte Colony-Stimulating Factor
4
Albumin-Bound Paclitaxel
4
tipifarnib
3
pertuzumab
3
pegfilgrastim
3
Thiotepa
3
Taxes
3
Tamoxifen
3
Surgical Procedures, Operative
3
Melphalan
3
Fluorouracil
3
Chemotherapy, Adjuvant
3
Capecitabine
3
130-nm albumin-bound paclitaxel
3
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Immunohistochemistry
2
Flow Cytometry
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Inflammatory Breast Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts